Bio-Thera Solutions Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bio-Thera Solutions Ltd.
Keeping Track: Novartis Entresto Wins Expanded Heart Failure Claim; Padcev, Vicineum Seek Bladder Cancer Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
China’s Bio-Thera is continuing its journey to bring biosimilars to patients across the globe, with its BAT1706 biosimilar bevacizumab candidate accepted for filing by the US Food and Drug Administration.
China’s Bio-Thera has struck a licensing deal with Biomm that will give the Brazilian company exclusive rights to market the BAT1706 bevacizumab biosimilar in its home market.
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
- Generic Drugs
- Drug Discovery Tools
- Other Names / Subsidiaries
- Biotech Biopharmaceutical Co., Ltd.